Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aspira Womens Health Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
AWH
Nasdaq
2835
https://aspirawh.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aspira Womens Health Inc
Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 28th, 2024 11:30 am
Aspira Women’s Health Announces New Time for its Fourth Quarter and 2023 Year End Earnings Results and Call
- Mar 25th, 2024 12:00 pm
Aspira Women’s Health to Present at the MedInvest Biotech & Pharma Investor Conference
- Mar 21st, 2024 12:00 pm
Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President
- Mar 18th, 2024 12:00 pm
Aspira Women’s Health to Announce Fourth Quarter and 2023 Year End Earnings Results and Host a Conference Call on Thursday, March 28, 2024
- Mar 11th, 2024 12:00 pm
Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
- Feb 22nd, 2024 1:30 pm
Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)
- Feb 12th, 2024 1:00 pm
Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines
- Feb 6th, 2024 1:00 pm
Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement
- Jan 25th, 2024 1:00 pm
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
- Jan 25th, 2024 12:30 pm
Bullish Aspira Women's Health Insiders Loaded Up On US$702.9k Of Stock
- Jan 4th, 2024 12:17 pm
Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024
- Dec 19th, 2023 1:00 pm
Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024
- Dec 14th, 2023 1:00 pm
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT
- Dec 8th, 2023 2:46 pm
New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT
- Dec 7th, 2023 2:20 pm
Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis
- Dec 6th, 2023 1:00 pm
Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)
- Nov 28th, 2023 1:00 pm
Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)
- Nov 27th, 2023 2:47 pm
Aspira Women’s Health Reports Third Quarter 2023 Financial Results
- Nov 13th, 2023 9:05 pm
Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch
- Nov 9th, 2023 1:00 pm
Scroll